- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Jeff Patton Reflects on OCM Performance Period 4 Results, Taking on 2-Sided Risk
Jeff Patton, MD, chief executive officer of Tennessee Oncology, weighs in on Oncology Care Model (OCM) performance period 4 results and taking on 2-sided risk.
Jeff Patton, MD, chief executive officer of Tennessee Oncology, weighs in on Oncology Care Model (OCM) performance period 4 results and taking on 2-sided risk.
Transcript
With OCM performance period 4 results now out, how did the results compare with the last 2 performance periods?
So, very similar. Every period we’ve generated savings against the target but every period we’ve not gotten a performance payment. The good news is as it applies to 2-sided risk, that means we would not have had any recruitment, so I think most likely we’re going to go and do 2-sided risk.
What are your thoughts on taking on 2-sided risk?
Risk is risk, so it makes everybody nervous, but with 4 consecutive performance periods where we’re in what we call the safe zone, we have a comfort level. We are investigating stop loss or reinsurance and I’ll have a lot more confidence if I have an insured downside.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More
